“The question is no longer whether AI belongs in life sciences. The question is whether your organization can govern it well enough to survive what comes next.”
Life sciences organizations know what AI can do. What most don’t yet have is the infrastructure to do it safely, repeatably, and in a way that survives regulatory scrutiny.
In this comprehensive whitepaper, USDM’s AI Center of Excellence lays out the operational framework to close that gap, covering the AI system lifecycle, partner platform risks, vendor assessment, citizen development, and how to get started in 90 days.
Download the White Paper >>>
What’s Inside
8 chapters. 37 pages. Everything you need to govern AI in a regulated environment.
- Part 1: The State of AI in Life Sciences —Why the pilot-to-production failure rate is 70–80%, and what’s different in 2026.
- Part 2: The AI System Lifecycle — A six-stage governance-integrated framework from ideation to decommissioning.
- Part 3: The Four Strategic Pillars for AI Value — How to anchor every AI initiative to revenue, efficiency, innovation, or risk mitigation.
- Part 4: Partner AI — The Compliance Blind Spot — What happens when Veeva, Box, ServiceNow, and Microsoft activate AI in your validated GxP environments without your action.
- Part 5: AI Vendor Assessment & Third-Party Risk Management — Why TPRM must now include AI, and how to assess vendors across six dimensions.
- Part 6: The Citizen Development Frontier — How to enable business-led AI development inside GxP guardrails.
- Part 7: USDM’s Expanded AI Service Portfolio — From AI Maturity Assessments to AI-Governance-as-a-Service (AIGaaS).
- Part 8: The 90-Day Pathway — Three entry points to establish your governance baseline fast.
Why This Matters Now
Three forces are converging in 2026 with unusual urgency:
- The EU AI Act high-risk enforcement provisions take effect in August 2026 requiring conformity assessments, technical documentation, and ongoing monitoring.
- Partner platforms like Veeva, Box, and ServiceNow are embedding AI directly into your validated GxP environments, often without explicit customer action.
- Board-level pressure to reduce compliance costs by 15–25% while simultaneously accelerating digital transformation.
Organizations that build unified AI governance infrastructure will find it a competitive advantage. Those that don’t face a new category of regulatory exposure.
Who This is For
This whitepaper is written for:
- Quality and Regulatory Affairs leaders managing AI adoption in GxP environments
- CIOs and CTOs responsible for validated platform governance
- Chief AI Officers and Digital Transformation leaders building scalable AI programs
- Compliance and Validation teams navigating FDA, EU AI Act, and ISO 42001 simultaneously
Download the White Paper >>>
Key Stats from the Paper
- 70–80% failure of enterprise AI pilots to reach production
- 20–40% higher cost to operate an under-optimized Veeva Vault
- 30–50% reduction in administrative overhead with the right AI governance model
- 35–45% reduction in compliance program costs using a unified framework
Contributors to White Paper
- John Petrakis, Chief AI Officer
- David Blewitt, VP of Digital Trust and AI Governance
- Enric Cullell, AI Quality Lead
- Elena Mirón, AI Program Manager
- Lisa Om, VP Marketing & Communications
Want proof that AI works in regulated environments? Download USDM’s AI in Life Sciences: 47 Use Cases for Quality, Regulatory, Clinical, and Manufacturing Teams — with quantified outcomes and inspection-ready architecture to help you move from pilot to production with confidence.